Top 5 Health Care Stocks That Are Preparing To Pump In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Apollomics, Inc. APLM

• EF Hutton initiated coverage on the stock with a Buy rating and a $25 price target. The company’s stock has a 52-week low of $3.71 .
• RSI Value: 8.47
• APLM Price Action: Shares of Apollomics rose 59.7% to close at $6.45 on Tuesday.

YS Biopharma Co., Ltd. YS

• YS Biopharma reported preliminary total revenue of $103 million, representing a year-over-year growth of 30%. "Our vaccine revenues grew robustly in Fiscal Year 2023, despite persistent macroeconomic uncertainties," commented Dr. David Shao, Director, President and CEO of YS Biopharma. The company’s stock has a 52-week low of $1.32.
• RSI Value: 6.79
• YS Price Action: Shares of YS Biopharma fell 8.2% to close at $1.45 on Tuesday.

AngioDynamics, Inc. ANGO

• AngioDynamics reported worse-than-expected Q3 revenue and reduced its 2023 revenue guidance. "We continued to make solid progress during the quarter executing on our strategic plan. Auryon, AlphaVac, NanoKnife, and our Med Device portfolio were bright spots during the third quarter, and while we experienced continued softness in AngioVac, we have taken steps to address the performance, and it remains an important driver for AngioDynamics’ growth," said Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. The company’s stock has a 52-week low of $8.50.
• RSI Value: 29.65
• ANGO Price Action: Shares of AngioDynamics fell 2.4% to close at $8.56 on Tuesday.

T2 Biosystems, Inc. TTOO

• On March 30, T2 Biosystems received a notice of delisting or failure to satisfy a continued listing rule or standard from Nasdaq. The company’s 52-week low is $0.34.
• RSI Value: 17.85
• TTOO Price Action: Shares of T2 Biosystems fell 1.8% to close at $0.3464 on Tuesday.

Esperion Therapeutics, Inc. ESPR

• Esperion reported co-promotion agreement with Currax Pharmaceuticals LLC. "We are excited to partner with Currax through the end of 2023 to continue raising awareness of NEXLETOL and NEXLIZET," said Sheldon Koenig, President and Chief Executive Officer of Esperion. The company has a 52-week low of $1.12.
• RSI Value: 24.55
• ESPR Price Action: Shares of Esperion Therapeutics dropped 1.6% to close at $1.20 on Tuesday.

Read More: Over $1M Bet On Stronghold Digital Mining? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying